𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The predicted impact of vaccination on human papillomavirus infections in Australia

✍ Scribed by Megan A. Smith; Karen Canfell; Julia M.L. Brotherton; Jie-Bin Lew; Ruanne V. Barnabas


Publisher
John Wiley and Sons
Year
2008
Tongue
French
Weight
395 KB
Volume
123
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Vaccines based on human papillomavirus (HPV) 16 and 18 virus‐like particles have the potential to prevent ∼70% of cervical cancers. In Australia, public vaccination against HPV commenced in April 2007, and includes routine vaccination of females aged 12–13 years, and a 2‐year school and GP‐based catch‐up in females aged 12–26 years. The objectives of this study were to estimate initial vaccination coverage rates, to describe current patterns of sexual behavior in young females, and to predict the impact of vaccination on HPV16 infections. We reviewed early coverage data, estimating that coverage in 2007/2008 will reach 86% (feasible range 67–90%) for 12‐ to 13‐year‐old girls, with lower rates attained in older females. A review of survey data found that the median age of first intercourse in Australian females is 16 years, with ∼90% of women sexually active at 22 years. Using these data, we performed an analysis of HPV transmission to predict the impact of vaccination on HPV infection rates. The public program is predicted to result in a reduction in the age‐standardized incidence of HPV16 infections of 56% by 2010 (feasible range 48–61%), and 92% by 2050 (feasible range 76–95%). Elective vaccination of older women and vaccination of males may provide some incremental gains, but the benefits to women of vaccinating males will be less if coverage of females remains high. In conclusion, the current vaccination program is expected to result in a substantial and rapid reduction in the incidence of HPV16 in Australia. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Human papillomavirus infection among you
✍ Showket Hussain; Mausumi Bharadwaj; Vilas Nasare; Malasha Kumari; Shashi Sharma; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract High‐risk human papillomaviruses (HR‐HPVs) are the causative agents of cervical cancer and prophylactic HPV vaccination has been recommended for adolescents but no data are available on the prevalence of HPV infection among adolescents in India. Self‐collected midstream urine samples fr

Cancer registries and monitoring the imp
✍ Mona Saraiya; Marc T. Goodman; S. Deblina Datta; Vivien W. Chen; Phyllis A. Wing 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB

TABLE 1 Results From an Ad Hoc Meeting Conducted by the Pan American Health Organization on Important Biologic Endpoints for Human Papillomavirus Vaccine Surveillance Endpoints for HPV Surveillance and Measurement Indicators Endpoint Measurement Indicator Genital HPV infections Changes in prevalence

Human papillomavirus in a rural communit
✍ Marc F.D. Baay; Eyrun F. Kjetland; Patricia D. Ndhlovu; Vanessa Deschoolmeester; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

## Abstract Cervical cancer is a leading cause of cancer‐related deaths in developing countries, and the human papillomavirus (HPV) is linked etiologically to cervical cancer. Hence, a vaccine which prevents HPV‐associated cervical cancer would have the most impact in developing countries, includin

Cervical infections by multiple human pa
✍ Barbara Dal Bello; Arsenio Spinillo; Paola Alberizzi; Stefania Cesari; Barbara G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

## Abstract A large proportion of human papillomavirus (HPV) infections is sustained by multiple genotypes. The effect of multiple infections on the risk of cervical intraepithelial neoplasia (CIN) and the potential efficacy of vaccine on these infections are controversial. We performed viral typin